Panel · Use case · Pharmacovigilance

Emerging Safety Signal Reassessment.

LiveBenefit-Risk Panel

A new signal has emerged on a marketed product. Does the balance remain favourable, and what response is proportionate?

DecisionWhether the balance remains favorable, and the proportionate response

FunctionsSafety, regulatory, medical, real-world evidence

ReaderSafety and regulatory leads

Not askedA regulatory submission

DepthStandard, four seats

Emerging Safety Signal Reassessment is a ready-made use case for Pharmacovigilance. It ships under the Benefit-Risk Panel template.

For drug safety leads. You get the effects table, each seat's conclusion, the weighing matrix, the uncertainties and the risk-minimisation measures. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

A new signal has emerged on a marketed product. Does the balance remain favorable, and what response is proportionate?

Who weighs

CIOMS Working Group IV set out a method for reassessing an established balance when a safety problem arises. The benefit is known, and the new risk is the variable.

Seat	What it weighs	What it works from
Head of Pharmacovigilance	The strength of the signal, its seriousness and what is known about frequency.^{2European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1).}	The signal management process.
Regulatory Strategist	What response is proportionate: routine label change, a communication, extra measures, or more.^{2European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1).,3European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}	GVP Modules IX and XVI.
Global Medical Affairs Director	How much the benefit matters to patients who would be affected.	Clinical evidence.
Global Real-World Evidence Lead	What databases can show about the signal and how reliable.	Observational data sources.

What the assessment does

Re-weighing, not a new approval. The benefit is established, so the report starts from it and asks how much the new risk moves the balance.^{1CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998.}

Proportionate response. The range runs from a routine label change to withdrawal. The report places the response on that range and states what evidence would move it.^{1CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998.,3European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}

Effectiveness of measures. Each measure has an owner and a way to judge whether it worked.^{3European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}

Recommended length

Standard

Four functions read the effects differently. Standard depth gives each a seat and shows the weighing matrix and the risk minimization table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the assessment makes

The assessment states what it assumes about the evidence and the setting, and says what each gap limits. Examples for this decision:

The signal reflects a true association and not a reporting effect.
The size of the benefit has not changed since approval.
Prescribers will act on the communication.

Standards, guidance and sources

Frame

CIOMS Working Group IV, benefit-risk balance for marketed drugs: evaluating safety signals.^{1CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998.}
EMA, GVP Module IX: Signal management (Rev. 1).^{2European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1).}
EMA, GVP Module XVI: Risk minimisation measures.^{3European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any rate computed from spontaneous reports, any claim that the benefit is unchanged without data, and any measure with no way to judge its effect.

What arrives

Decision and therapeutic context
Benefit-risk conclusion
Effects table
What each seat concludes
Weighing matrix by seat and criterion
Uncertainties and sensitivity
Risk minimisation and monitoring
What would change the balance

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists, and the decision stays with you.

It does not decide whether a signal is validated. That belongs to the safety committee.

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998. The PDF was unreadable; method as described in secondary summaries.
[2] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1). Scope as given in EMA’s listing; not read in full.
[3] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures. Not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.